woensdag 28 oktober 2020

A biochemical perspective on nutrition, immunomodulation and counteracting of oxidative stress (1): quercetin, polysaccharides and curcumin compounds

"Super foods" don't exist. There is no miracle drug, nutrient or other molecular substance, be it synthetic or biological, to prevent disease like a "one-size-fits-all" solution. One cannot claim a nutrient to prevent the occurrence of infections. 

Of relevance is that certain nutrients can contribute to the targeting of mechanisms underlying diseases. Two major mechanisms underlying disease are failure of the innate and adaptive immunity to establish an adequate response to pathogens and reactive oxidative stress (ROS), a non-psychological, biomolecular phenomenon. 

In this message, I will discuss a selection of  research on biochemical substances found in nutritives. Note that questions regarding absorption and metabolism of nutrients remain to be answered.

1.    Quercetin;
1.1. The flavonoid and flavonol group;
1.2. Quercetin inhibits the NF-kB pathway and LPS-induced STAT-1 macrophage activation;
1.3. Toxicity and carcinogenic risk of quercetin;
1.4. Antioxidant properties of quercetin to target Oxidative Stress and Reactive Nitrogen Species;
1.5  The bioavailability question: aglycones and glycosides;
2     Polysaccharides;
2.1. Antioxidant and immunomodulatory properties;
2.2. Antifibrotic activity of vegetable polysaccharides against BLM-fibrosis;
3     Curcumin compounds;
3.1. Curcumin analogs suppress IL­1-β and COX-2 to attenuate hyperinflammation;
4     Warning: drug interactions with grapefruit flavonoids and non-flavonoids;
5     Next feature

1. Quercetin (3,3,4,5,7-pentahydroxyflavone, see: Quercetin, in: ScienceDirect, an overview)

1.1. The flavonoid and flavonol group
Quercetin is a flavonol, a polyphenolic benzene compound found in vegetables and fruits.
Quercetin concentrations are high in red onions and also found in capers, blackberries, cranberries, apples, buckwheat, citrus fruits, garlic, ginger, peppers, turmeric, grapes, elderberries, kale (cavolo nero), (green) tea and wine ("Flavonols and Kaempferols", in: Berries and Related Fruits, Encyclopedia of Fruit and Health 2016, P364-371). Catechin compounds in berries, wine and tea leaves are not actual flavonoids (Principles and Practice of Herbal Phytotherapy 2013, P17-82). While quercetin levels decrease with duration of storage and food procession, quercetin levels in strawberries increase when stored at -20C for 9 months (Chapter 2- Quercetin and Trypthanthrin: Two Broad Spectrum Anticancer Agents for Future Interventions, The Enzymes Vol. 37, 2015, P43-72). Quercetin rutinoside, found in citrus fruits, is mentioned to be irritating or allergenic to some people ("Quercetin", in: Polyphenols: Mechanisms of Action in Human Health and Disease, 2018, P403-413).

Strawberries: stored for 9 months at -20C increases its quercitin levels (courtesy of Mercedes Bouter LL.M.)

1.2 Quercetin inhibits the NF-kB pathway and LPS-induced STAT-1 macrophage activation
Quercetin is associated with NF-kB inhibition, thereby reducing cytokine production. In vitro, quercetin was found to downregulate the inflammatory response of bone marrow-derived macrophages. Quercetin inhibits Lipopolysaccharide (LPS)-induced macrophage activation of STAT-1 and IFN-γ-induced STAT-1 activation ("Quercetin", in: Anti-inflammatory Properties of Cinnamon Polyphenols and Their Monomeric Precursors, Polyphenols in Human Health and Disease Vol. 1, 2014, P409-425; see also: Bioactive effects of quercetin in the central nervous system: Focusing on the mechanisms of actions, Biomedicine & Pharmacotherapy Vol. 84, December 2016, P892-908).
Quercetin suppresses anaphylactic responses in vitro by stabilization of mast cell membranes and inhibits enzymes responsible for production of leukotrienes (LTs), derived from arachidonic acid metabolism (literally: peanut butter acid) (see: Leukotrienes, in: Mast Cells, Basophils and Asthma; The Allergic Patient, in: Integrative Medicine (Fourth Edition) 2018, P300-309).

Quercetin is also associated with suppression of anti-inflammatory M2 macrophage and the anti-inflammatory cytokine IL-10 in vitro in obese models. However, overall quercetin was found to reduce chronic inflammation by suppression of NF-kB, TNF-alpha and oxidative stress (Quercetin suppresses immune cell accumulation and improves mitochondrial gene expression in adipose tissue of diet-induced obese mice, Molecular Nutrition and Food Research Vol. 60, Issue 2, February 2016, P300-312).

1.3 Toxicity and carcinogenic risk of quercetin
Quercetin supplementation might enhance nephrotoxic effects in predamaged kidneys and promote tumor development in estrogen-dependent cancers (Safety Aspects of the Use of Quercetin as a Dietary Supplement, Molecular Nutrition and Food Research Vol. 61, Issue 1, January 2018). Phytoestrogens could also induce estrogen-dependent cancers: phytoestrogens mimic estrogen 17β-estradiol (E2). Quercetin does not decrease E2-induced oxidant stress. Inhibition of Cathegol-O-Methyltransferase (COMT) by quercetin prolongs exposure to 17β-estradiol and cathegol estrogens, thus inducing the risk of carcinogenic activity and chronic exposure to metabolic oxidative stress (Dietary quercetin exacerbates the development of estrogen-induced breast tumors in female ACI rats, Toxicology and Applied Pharmacology Vol. 247, Issue 2, 1 September 2010, P83-90).

1.4 Antioxidant properties of quercetin to target Oxidative Stress and Reactive Nitrogen Species
Quercetin may stimulate cell defenses against oxidative stress (Reactive Oxygen Species and Reactive Nitrogen Species) by induction of Nrf2-ARE and Paraoxonase-2 (PON2). However, the neuroprotective effect on astrocytes depends on whether quercetin metabolites are able to pass the Blood-Brain Barrier, which requires coadministation of alpha-tocopherol to enhance transport (Mechanisms of Neuroprotection by Quercetin: Counteracting Oxidative Stress and More, Oxidative Medicine and Cellular Longevity 2016; 2016: 2986796; see also: Potential for Brain Accessibility and Analysis of Stability of Selected Flavonoids in Relation to Neuroprotection in Vitro, Brain Research Vol. 1651, 15 November 2016, P17-26). Another counterinflammatory mechanism of quercetin is the blocking of poly-unsaturated fatty acid (PUFA) through inhibition of lipoxygenase.

Seemingly paradoxical
, quercetin can increase NF-kB activation through phosphorylation of Thr23 and Ser22. Activation of the NF-kB pathway might be the defense mechanism by tumor cells in response to quercetin, but NF-kB activity through nuclear factor IKK-alpha and IKK-beta phosphorylation has probable anti-carcinogenic properties. Whether patients would benefit from quercetin supplementation, is gene-dependent (Quercetin inhibits prostate cancer by attenuating cell survival and inhibiting anti-apoptotic pathways, World Journal of Surgical Oncology 2018; 16: 108). In vivo, Cisplatin and Quercetin, (CP and QC) act synergistically with hyperthermia (43 °C) to inhibit tumor growth; however, caution is warranted with regards to anti-oxidative effects of quercetin on cisplatin, which might impair cisplatin therapy (Interactions between Cisplatin and Quercetin at Physiological and Hyperthermic Conditions on Cancer Cells in Vitro and in Vivo, Molecules 2020 Jul; 25(14): 3271).

1.5 The bioavailability question: aglycones and glycosides
The reported optimal dose for quercetin and kaempferol to have cardiovasculoprotective effects is 500 mg of the aglycone form. Flavonols are divided into aglycones and glycosides. Aglycones are fat-soluble (lipophilic), while glycosides, sugar structures, are water-soluble (lipophobic). Dietary fat intake was shown to increase the absorption of quercetin glycones from the intestines. While kaempferol (found in cichorei endive and broccoli) is the most stabile compound, the bioavailability of quercetin flavonols is higher. Of quercetin sources, the 24-hour urinary excretion is highest for red onions; red wine and tea perform poorer (Dietary Quercetin and Kaempferol: Bioavailability and Potential Cardiovascular-Related Bioactivity in Humans, MDPI Nutrients 2019, 11(10), 2288).

Recommended literature

Therapeutic potential of quercetin as a cardiovascular agent, European Journal of Medicinal Chemistry Vol. 155, 15 July 2018, P889-904.
In this study, quercetin was found to inhibit LDL (Low Density Lipoprotein) oxidation, to reduce adhesion molecules and to protect against platelet aggregation.

Prophylactic efficacy of Quercetin in ameliorating the hypoxia induced vascular leakage in lungs of rats, PLoS One 2019; 14(6);
Pleiotropic beneficial effects of epigallocatechin gallate, quercetin and delphinidin on cardiovascular diseases associated with endothelial dysfunction, Cardiovascular and hematological agents in medicinal chemistry 2013 December;11(4):249-64;
Quercetin in Hypoxia-Induced Oxidative Stress: Novel Target for Neuroprotection, International Review of Neurobiology Vol. 102, 2012, P107-146;

2. Polysaccharides

2.1 Antioxidant and immunomodulatory properties
In Paragraph 1  I discussed the pharamcological and prophylactic potential of quercetin, as well as risks of dietary or supplementary intake of quercetin. Quercetin is known for its immunomodulatory and antioxidant properties: it is associated with NF-kB inhibition, suppression of Lipopolysaccharide (LPS)-induced macrophage activation of STAT-1 and TNF-alpha and reduction of Oxidative Stress. Oxidative Stress, NF-kB, elevated levels of IL-1, IL-6, TNF-alpha, cell adhesion molecules ICAM-I, VCAM-I and P-selectin are associated with hypoxia. In addition, vegetable polysaccharides are associated with specific antifibrotic properties.

2.2  Antifibrotic activity of vegetable polysaccharides against BLM-fibrosis
In BLM-fibrosis (bleomycin-stimulated fibrosis), plant polysaccharides are shown to alleviate inflammation of pulmonary alveoli, reduction of hyaluronic acid and deposition of collagen fibrils. Seaweed sargassum hemiphyllum attenuates the increased expression of TIMP-1, CXCL1, MCP-1, MIP-2, and interleukin-1 receptor antagonist (IL-1RA). Seaweed, administered in therapeutic doses, is able to arrest TGF-β1-induced human embryonic pulmonary fibroblast (HEPF) cell proliferation, collagen deposition and matrix metalloproteinase activity. Ginsen has a high binding affinity for TGF-β1. Basil suppresses TGF-β1-induced fibrotic activity and marine algae inhibit heparin/heparan sulfate-TGF-β1-interaction (A review for natural polysaccharides with anti-pulmonary fibrosis properties, which may benefit to patients infected by 2019-nCoV, Carbohydrate Polymers 2020 Nov 1; 247: 116740).

Ophiocordyceps lanpingensis (OLP) funghi polysaccharides suppress expression levels of TNF-α, IL-1β, IL-6 (Macrophage M1-secreted), OSM, IL-10 and IL-13 (Macrophage M2-secreted) genes in lung tissues. OLP decreases MCP-1 and decreases Reactive Oxygen Species/Oxidative Stress though counteracting lipid peroxidation activity. These mechanisms show the potential of OLP to inhibit pulmonary fibrosis through reduction of macrophages and through antioxidant activity targeting lipid peroxidation (Ophiocordyceps lanpingensis polysaccharides attenuate pulmonary fibrosis in mice, Biomedicine & Pharmacotherapy Vol. 126, June 2020).

3. Curcumin compounds

3.1 Curcumin analogs suppress IL­1-β and COX-2 to attenuate hyperinflammation
Curcumin analogs are shown to inhibit the expression of TNF-alpha and IL-6 by downregulation of the Extracellular signal-regulated kinase (ERK) and to suppress IL­1-β in epithelial cells and Cyclooxygenase 2 (COX-2) (Anti-inflammatory effects of novel curcumin analogs in experimental acute lung injury, Respiratory Research 2015; 16(1): 43). The function of COX-2 is to synthesize prostaglandins involved in the "inflammatory soup". A 2008 study found curcumin, adjusted as a NF-kB blocker, to attenuate hypoxia-induced lung leakage (Role of Oxidative Stress and NF-kB in Hypoxia-Induced Pulmonary Edema, Journal of Experimental Biology and Medicine Vol. 233, Issue 9, 2008).

In vivo studies have shown that curcumin inhibits inflammatory cytokines IL-1, IL-6, IL-8, Tumor Necrosis Factor-alpha (TNF-α), IKKβ and IL-1β. Curcumin decreases expression of inflammatory and profibrotic factors such as MCP1, CXCL1, CXCL10, MMP-2, Interferon-gamma (IFN-γ) and MMP-9.
Curcumin is mentioned to act on p65 to block the NF-κB pathway. Inhibition of Toll-like receptor 2, 4 and 7 (TLR 2, 4 and 7) expression and TRAF6 genes reduces viral inflammation. Curcumin compounds regulate IL-10, which in its turn is a regulator of TNF-alpha, Reactive Oxidative Stress and Treg cells (IL-10 plays an important role as an immune-modulator in the pathogenesis of atopic diseases, Molecular Medicine Reports 2008;1(6):837-42). IL-10 is an anti-inflammatory cytokine that suppresses the expression of Intercellular Adhesion Molecule-1 (ICAM-1) in the vasculature, thereby reducing tissue damage. Notably, curcumin activates the Nrf2-hemeoxygenase-1 (Nrf2-HO-1)-axis, an antiviral and immunomodulating mechanism to protect the pulmonary alveoli (The Inhibitory Effects of Curcumin on Virus-Induced Cytokine Storm and its Potential Use in the Associated Severe Pneumonia, Frontiers in Cell and Developmental Biology, 12 June 2020).

Curcumin has also been shown to upregulate ACE2 and Angiotensin II Type II receptor and downregulate Angiotensin II type I receptor, in order to restore balance in the Renin-Angiotensin-Aldosterone System (RAS/RAAS) (Potential effects of curcumin in the treatment of COVID-19 infection, Phytotherapy Research, 19 May 2020).

Beside anti-Reactive Oxidative Stress (ROS) properties, curcumin compounds carry out mechanisms to protect lung tissue:
1. Curcumin compounds regulate anti-inflammatory IL-10;
2. Curcumin activates antiviral activity and immunomodulation via the Nrf2-OH-1-axis.

A major downside is that turmeric curcumin is not a stable compound. The properties of curcumin, however, offer pharmaceutical options.

Zeaxanthin (a carotenoid found in the eye retina) and quercetin!


Bell peppers in green, red and orange; chili peppers, garlic, red onions, curcuma, ginger

4. Warning: drug interactions with grapefruit flavonoids and non-flavonoids

Grapefruit: Although grapefruits offer a rich source of flavonoids (naringenin, naringin, quercetin and kaempferol) and non-flavonoids (bergamottin), naringin and the furinocoumarin bergamottin are able to inhibit CYP3A4 in the small intestines. CYP3A4 enzymes break down drugs. Inhibition of CYP3A4 creates the risk of an actual overdose. Immunosuppressants, calcium antagonists (cardiovascular medication) and muscle relaxants such as benzodiazepines interact with grapefruit furanocoumarins (Grapefruit and drug interactions, Prescrire International 2012 Dec;21(133):294; Interaction of Grapefruit Juice and Calcium Channel Blockers, American Journal of Hypertension Vol. 19, Issue 7, July 2006).

5 Next feature
Next feature, I will discuss immunomodulatory properties of nutrition. Among one of the prominent compounds is the steroid hormone commonly known as Vitamin D3, calcitriol, in its active form 1,25-dihydroxyvitamin D3 = 1,25(OH)2D3.

Also worth mentioning in a next feature is a compound with presumed anti-inflammatory properties: bromelain, found in pineapples. Bromelain compounds in synergy with acteylcysteine is hypothesized to exert antiviral activity.

Bell pepper is a source of zeaxanthin, retinol (Vit A), ascorbic acid (Vit C) and flavonoids


Do not overdo it! While only large amounts of chili peppers/capsicum annuum will contain significant nutritional values of Vitamin A and C, its main ingredient capsaicin (found in the glands of the membranes) is highly irritant when ingested at even lower amounts.













donderdag 22 oktober 2020

Immunological and inflammatory factors in COVID-19/SARS-CoV-2 infection: a research collection

1. Questions on COVID-19 to be answered
ACE2, COVID-19 Infection, Inflammation and Coagulopathy: Missing Pieces in the Puzzle, Frontiers in Physiology 2020; 11: 574753;

ADAM
ADAM9 is a Novel Product of Polymorphonuclear Neutrophils: Regulation of Expression and Contributions to Extracellular Matrix Protein Degradation During Acute Lung Injury, Journal of Immunology 2014 Sep 1; 193(5): 2469-2482;
The Role of Metalloproteinase ADAM17 in Regulating ICOS Ligand-Mediated Humoral Immune Responses, The Journal of Immunology Vol. 193, Issue 6, 15 September 2014;
B cell ADAM17 controls T cell independent humoral immune responses through regulation of TACI and CD138, Biochemical and Biophysical Research Communications Vol. 552, Issue 2, 5 February 2020;
ACE2/ADAM17/TMPRSS2 Interplay may be the Main Risk Factor for COVID-19, Frontiers Inflammation, 07 October 2020;
ADAM17, the TNF-alpha convertase, ScienceDirect

ALI (Acute Lung Injury) due to COVID-19
Inhibition of metalloproteinases in therapy for severe lung injury due to COVID-19, Medicine in Drug Discovery 2020 Sep; 7: 100052;

Autophagy
Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19?, Life Sciences Vol. 262, 1 December 2020;

Caveolin-1, ARDS and ALI
Caveolin-1: a critical regulator of lung injury, American Journal of Physiology, Lung Cellular and Molecular Physiology 2011 Feb; 300(2);
Inflammation-induced caveolin-1 and BMPRII depletion promotes endothelial dysfunction and TGF-β-driven pulmonary vascular remodeling, Lung Cellular and Molecular Physiology 2017 May 1; 312(5);

Clinical Immunology

Long-term infection of SARS-CoV-2 changed the body's immune status, Clinical Immunology 2020 Sep; 218: 108524;

Contact system involvement
The contact activation system as a potential therapeutic target in patients with COVID-19, Research and Practice in Thrombosis and Haemostasis Vol. 4, Issue 4, May 2020;

Cytokine profile
Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis and comparison with other inflammatory syndromes, Lancet Respiratory Medicine October 16, 2020;

Elevation of liver enzymes in COVID-19
Serum Activity of Liver Enzymes is Associated with Higher Mortality COVID-19: A Systematic Review and Meta-Analysis, Frontiers Gastroenterology, 22 July 2020;

Ethnic profiles
Ethnic differences in alpha-1 antitrypsin deficiency allele frequencies may partially explain national differences in COVID-19 fatality rates, FASEB Journal 2020 Sep 22;

FOXP3 (Forkhead family of transcription responsible for Treg development)
FOXP3- an overview, ScienceDirect;
T-cell Hyperactivation and Paralysis in Severe COVID-19 Infection Revealed by Single-Cell Analysis, (CD25+ hyperactivation facilitates coronavirus entry by producing Furin; FOXP3-mediated negative feedbacks are impaired) Frontiers Immunological Tolerance and Regulation, 08 October 2020;
The many functions of FOXP3+ Regulatory T cells in the intestine, Frontiers T cell Biology, 20 October 2020;

Genetic profile
Host/genetic factors associated with COVID-19 call for precision medicine (NETs, NETosis and DAMPS), Precision Clinical Medicine 2020 Vol. 3, Issue 3, September 2020;

Interferons (IFN-)
SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity is Increased by a Naturally Occurring Elongation Variant (anti-IFN I and NLS), Cell Report Vol. 32, Issue 12, 108185, September 22, 2020;
The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I Interferon (IFN) signaling pathway (SARS-CoV-2 inhibits IFN-β activation and the NF-kB pathway, ORF6 and ORF8 suppress innate immune functions), Virus Research Vol. 286, September 2020;
Heightened circulating Interferon-Inducible Chemokines and activated Pro-Cytolytic Th1-cell phenotype features COVID-19 aggravation in the second week, Frontiers Cytokines and Soluble Mediators in Immunity, 20 October 2020;

Interleukins (IL- )
Elevated IL-33 promotes expression of MMP2 and MMP9 via activating STAT3 in alveolar macrophages during LPS-induced acute lung injury (ALI), Cellular & Molecular Biology Letters 2018; 23:52;
IL-1 induces thromboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1-Receptor antagonist (IL-1Ra), Journal of Biological Regulators and Homeostatic Agents 2020 Aug 3;34(5);
Imperfect storm: is interleukin-33 the Achilles heel of COVID-19?, Lancet Rheumatology, 9 October 2020;

Macrophages
Targeting macrophages as a therapeutic option for COVID-19 (M1 and M2), Frontiers Inflammation Pharmacology, to be published;
Activated protein C and PAR1-derived peptides are anti-inflammatory by suppressing macrophage NLRP3 inflammasomes, Journal of Thrombosis and Haemostasis, 13 October 2020;
A critical role for suppressor of cytokine signalling 3 in promoting M1 macrophage activation in vitro and in vivo, Immunology 2014 Jan;141(1):96-110;
Protective effect op suppressing STAT3 activity in LPS-induced lung injury, Lung Cellular and Molecular Physiology 2016 Nov 1; 311(5);
Macrophage responses associated with COVID-19: A pharmacological perspective, European Journal of Pharmacology Vol. 887, 15 November 2020;
Alveolar macrophage dysfunction and cytokine storm in the pathogenesis of two severe COVID-19 patients, EBioMedicine Vol. 57, July 2020;
The lung macrophage in SARS-CoV-2 Infection: A Friend or a Foe?, Frontiers in Immunology 2020; 11: 1312;

MAPK signalling pathways

MAPK signalling pathways as molecular targets for anti-inflammatory therapy- from molecular mechanisms to therapeutic benefits, Biochimica et Biophysica Acta (BBA)- Proteins and Proteomics, Vol. 1754, Issue 1-2, 30 December 2005, p253-262;

Megakaryocytes

Development and characterisation of a novel, megakaryocyte NF-kB reporter cell line for investigating inflammatory responses, Journal of Thrombosis and Haemostasis, 09 October 2020;

Matrix Metalloproteinases (MMPs) and their role in Acute Lung Injury (ALI)
Elevated IL-33 promotes expression of MMP2 and MMP9 via activating STAT3 in alveolar macrophages during LPS-induced acute lung injury (ALI), Cellular & Molecular Biology Letters 2018; 23:52;
Upregulation of matrix metalloproteinase 9 (MMP9)/tissue inhibitor of metalloproteinase 1 (TIMP1) and MMP2/TIMP2 ratios may be involved in lipopolysaccharide-induced acute lung injury (LPS-induced ALI), Journal of International Medical Research 2020 Apr; 48(4);
Inhibition of metalloproteinases in therapy for severe lung injury due to COVID-19, Medicine in Drug Discovery 2020 Sep; 7: 100052;
Matrix Metalloproteinases in ALI: mediators of injury and drivers of repair, European Respiratory Journal Vol. 38 Issue 4, 2011;
Serum MMP-8 and TIMP-1 in critically ill patients with acute respiratory failure: TIMP-1 is associated with increased 90-day mortality, Anesthesia and analgesia 2014 Apr;118(4):790-8;

Natriuretic peptide in healthy individuals

Subclinical elevated B-type natriuretic peptide (BNP) indicates endothelial dysfunction contributing to hypoxia susceptibility in healthy individuals, Life Sciences Vol. 260, 1 November 2020;

Natural Killer Cells (NK-)
KLRD1 Killer Cell lectin-like receptor (CD94), gene id;

Neutrophil Extracellular Traps (NETs) and NETosis
Host/genetic factors associated with COVID-19 call for precision medicine (NETs, NETosis and DAMPS), Precision Clinical Medicine 2020 Vol. 3, Issue 3, September 2020;
Neutrophil Extracellular Traps (NETs) and Damage-Associated Molecular Patterns (DAMPs): Two Potential Targets for COVID-19 Treatment, Mediators of Inflammation 2020;2020;
Devilishly radical NETwork in COVID-19: Oxidative Stress, neutrophil extracellular traps (NET) and T cell suppression, Advances in Biological Regulation 2020 Aug; 77;
Tissue damage from neutrophil-induced oxidative stress in COVID-19, Nature Reviews Immunology 2020 Jul 29: 1-2;
Neutrophils and Neutrophil Extracellular Traps Drive Necroinflammation in COVID-19, Cells 2020 Jun; 9(6): 1383;
SARS-CoV-2-triggered NETs mediate COVID-19
, Journal of Experimental Medicine 2020 Dec 7; 217(12);

NLRP3 Inflammasome

Severe COVID-19: NLRP3 Inflammasome Dysregulated, Frontiers Immunology 2020; 11: 1580;

PAMPs (Pathogen-Associated Molecular Patterns)
Host/genetic factors associated with COVID-19 call for precision medicine (NETs, NETosis and DAMPS), Precision Clinical Medicine 2020 Vol. 3, Issue 3, September 2020;

Perspective from scientists

Surviving COVID-19: A disease tolerance perspective, Science Advances 2020 May; 6(18);

ROS (Reactive Oxidative Species) and Oxidative Stress (= biophysics)
Reactive Oxidative Species-Modulated Ca2+ release Regulates β2 integrin activation on CD4+CD28null T Cells of Acute Coronary Syndrome Patients, Journal of Immunology Vol. 205, Issue 9, 1 November 2020 (see edit);
Mild SARS-CoV-2 infections in children might be based on evolutionary biology and linked with host Reactive Oxidative Stress and antioxidant capabilities, New Microbes and New Infections Vol. 36, July 2020;

Suppressor of Cytokine Signalling (SOCS)
SOCS Proteins Participate in the Regulation of Innate Immune Response Caused by Viruses (feedback through Janus kinase and STAT), Frontiers in Immunology 2020; 11;
Suppressor of cytokine signalling (SOCS1) is a key determinant of differential macrophage activation and function, Journal of Leukocyte Biology Vol. 90, Issue 5, November 2011, p845-854;
SOCS3 Attenuates GM-CSF/IFN-y-Mediated Inflammation During Spontaneous Spinal Cord Regeneration, Neuroscience Bulletin 2020 Jul; 36(7): 778-792;

T cells
Decreased T cell populations contribute to the increased severity of COVID-19 (CD3+, CD4+ and CD8+ lymphocytes decreased in severe COVID), Clinica Chimica Acta Vol. 508, September 2020, P110-114;
T-cell Hyperactivation and Paralysis in Severe COVID-19 Infection Revealed by Single-Cell Analysis, Frontiers Immunological Tolerance and Regulation, 08 October 2020;
Tumor-derived soluble MIC ligands impair expression of NKG2D and T-cell activation, Nature 419, 734-738(2002), 17 October 2002;
COVID-19 and the Path to Immunity (boosting CD8+ and TH1 CD4+ T cells), JAMA 2020;324(13):1279-1281;
Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4+ T Cells in COVID-19, Cell 5 October 2020;

Th cells and Treg cells
Th17 and Treg cells function in SARS-CoV-2 patients compared with healthy controls, Journal of Cellular Physiology, 14 September 2020;
Heightened circulating Interferon-Inducible Chemokines and activated Pro-Cytolytic Th1-cell phenotype features COVID-19 aggravation in the second week, Frontiers Cytokines and Soluble Mediators in Immunity, 20 October 2020;

Therapeutic targets
Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement, Contact Activation and Kallikrein-Kinin System
, Frontiers Molecular Innate Immunity, 14 August 2020;
Nutraceuticals have potential for boosting the type I Interferon (IFN) response to RNA viruses including influenza and coronavirus (downregulation of NOX2 to enhance Toll-like Receptor 7 (TLR7) activity), Progress in Cardiovascular Diseases 2020 May-June; 63(3): 383-385;
Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients, Pharmacology & Therapeutics 2020 Sep; 213: 107587;
Caveolin-1: a critical regulator of lung injury, Lung Cellular and Molecular Physiology 2011 Feb; 300(2);
MMP8 Inactivates Macrophage Inflammatory Protein-1alpha to Reduce ALI in mice, Journal of Immunology 2010 Feb 1; 184(3);
Protective Effect of Epigallocatechin-3-Gallate (EGCG) in Diseases with Uncontrolled Immune Activation: Could Such a Scenario Be Helpful to Counteract COVID-19?, International Journal of Molecular Science 2020 Jul;21(14):5171;
Inhibition of metalloproteinases in therapy for severe lung injury due to COVID-19, Medicine in Drug Discovery 2020 Sep; 7: 100052;
IL-1 induces thromboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1-Receptor antagonist (IL-1Ra), Journal of Biological Regulators and Homeostatic Agents 2020 Aug 3;34(5);
New putative insights into neprisylin (NEP)-dependent pharmacotherapeutic role of roflumimast in treating COVID-19, Vol. 889, 15 December 2020;
Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19?, Life Sciences Vol. 262, 1 December 2020;


dinsdag 20 oktober 2020

SARS-CoV-2/COVID-19 Hypercoagulation, thrombosis, embolism and urokinase pathways: an up-to-date research collection

Haemostasis and vasculature: COVID-19 characterized by thrombosis and hypercoagulability

 
Below is a classic collection of verified and updated thrombosis research. I have selected sources that are applicable to COVID-19 as well as to mechanisms of coagulopathy in general.

ADAMTS-13's failure to cut Von Willebrand Factor (VWF)
ADAMTS13 activity, Von Willebrand Factor, Factor VIII and D-dimers in COVID-19 inpatients, Thrombosis Research 2020 Aug; 192: 174-175;
Targeting VWF levels and macrophage activation in severe COVID-19: Consider low volume plasma exchange and low dose steroid, Thrombosis Research 2020 Aug; 192:2;

Aspirin (Acetylsalicylic acid) use and cardiovascular management of COVID-19
Apirin Use is Associated with Decreased Mechanical Ventilation, ICU Admission, and In-Hospital Mortality in Hospitalized Patients with COVID-19, Anesthesia & Analgesia: October 21, 2020;
Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19?, Drugs 80, 1383-1396(2020);

Antiviral agents and interaction with anticoagulant drugs
Direct oral anticoagulants (DOAC) plasma levels' striking increase in severe COVID-19 patients treated with antiviral agents: The Cremona experience, Journal of Thrombosis and Haemostasis 2020 May 6;

Capillary hypertension

Effect of Coronavirus Disease 2019 in Pulmonary Circulation. The Particular Scenario of Precapillary Pulmonary Hypertension, Diagnostics (Basel) 2020 Aug; 10(8): 548;

Cardiovascular complications in COVID-19
Right Atrial Thrombus in Transient in a COVID-19 Patient: Clinical Echocardiographic Features--Case Report and Literature Review, SN Comprehensive Clinical Medicine 2020 Oct 8: 1-3;
Cardiovascular Implications of Patients with COVID-19, JAMA Cardiology 2020 Jul;5(7):1-8;
Coronavirus and Cardiovascular Disease, Myocardial Injury and Arrhytmia (all factors explained), JACC 2020 Oct 27; 76(17): 2011-2023;
COVID-19, myocardial edema and dexamethasone, Medical Hypotheses Vol. 145, December 2020;
Rescue venoarterial extracorporeal membrane oxygenation (ECMO) after cardiac arrest in COVID-19 myopericarditis, Cardiovascular Revascularization Medicine, 30 September 2020;

Acute myocardial injury is common in patients with COVID-19 and impairs their prognosis, BMJ Heart 2020 Aug; 106(15): 1154-1159;

COVID-19 Coagulopathy (CAC)
Coagulopathy in COVID-19: Focus on vascular thrombotic events, Journal of Molecular Cell Cardiology 2020 Sep; 146: 32-40;
SARS-CoV-2 and coagulation disorders in different organs, Life Science 2020 Nov 1; 260: 118431;
The coagulopathy, endotheliopathy and vasculitis of COVID-19, Inflammation Research 2020 Sep 12: 1-9;
Coagulopathy in COVID-19, Journal of Thrombosis and Haemostasis Vol. 18, Issue 9, September 2020, p2103-2109;
Systemic Inflammatory Response Syndrome is a Major Contributor to COVID-19-Associated Coagulopathy, Circulation 2020 Aug 11; 142(6): 611-614 (Note: PAI-1 and procoagulants are significantly elevated in COVID-19 as compared to other viruses);
Comment: checking for hyperhomocysteinemia in COVID-19, Journal of Thrombosis and Haemostasis, 08 October 2020;
Pulmonary intravascular coagulopathy in COVID-19 pneumonia, Lancet Rheumatology Vol. 2, Issue 8, E458, August 01, 2020;
The unique characteristics of COVID-19 coagulopathy, Critical Care 2020; 24: 360;

Coagulation markers
Specific coagulation markers may provide more therapeutic targets in COVID-19 patients receiving prophylactic anticoagulant (thrombin-antithrombin complex levels, TAT and plasmin-antiplasmin (PAP)), Journal of Thrombosis and Haemostasis, Vol. 18, Issue 9, September 2020, p2428-2430;

COVID-19 thrombotic activity: pathogenesis of coronavirus SARS-CoV-2

Characterization of heparin and SARS-CoV-2 Spike glycoprotein binding interactions, Antiviral Research Vol. 181, September 2020, 104873;
Multifactorial pathogenesis of COVID-19-related coagulopathy. Can defibrotide have a role in the early phases of coagulation disorders?, Journal of Thrombosis and Haemostasis, 21 July 2020;
Thrombotic Complications in Patients with COVID-19: Pathophysiological Mechanisms, Diagnosis and Treatment, Cardiovascular Drugs and Therapy Journal 2020 Oct 19: 1-15;
Pulmonary Arterial Thrombosis in COVID-19: Results from a Prospective, Single-Center, Clinicopathologic Case Series, Annals of Internal Medicine 2020 May 14;

Deep Vein Thrombosis (DVT)
Incidence of deep vein thrombosis among non-ICU patients hospitalized for COVID-19 despite pharmacological thromboprophylaxis, Journal of Thrombosis and Haemostasis Vol. 18, Issue 9, September 2020, p2358-2363;
Response to: Incidence of DVT among non-ICU patients hospitalized for COVID-19 despite thromboprophylaxis: hypoxia as a clinically relevant risk for DVT needs further investigation;

Embolism

Late Pulmonary Embolism after COVID-19 Pneumonia Despite Adequate Rivaroxaban Treatment, European Journal of Case Reports in Internal Medicine 2020; 7(7): 001790;
Pulmonary embolism: A complication of COVID-19 infection, Thrombosis Research 2020 Sep; 193: 79-82;
A Review of Venous Thromboembolism Phenomena in COVID-19 Patients, Current Problems in Cardiology 2020 Aug 28; 100692;
Pulmonary embolism in acute medicine: a case-based review incorporating latest guidelines in the COVID-19 era, British Journal of Hospital Medicine Vol. 81, Issue 6, 2 June 2020;
Pulmonary Embolism in Patients With COVID-19: Awareness of an Increased Prevalence (thrombosis in coronavirus is similar to SARS-1 (2003), differs from influenza; low incidence of DVT suggests pulmonary thrombosis rather than embolism), Circulation, Vol. 142, Issue 2, July 14, 2020;
COVID-19 Complicated by Acute Pulmonary Embolism, Radiology: Cardiothroracic Imaging Vol. 2, nr. 2, 2020;
Diagnosis and Treatment of Pulmonary Embolism During the COVID-19 Pandemic, Chest Journal, August 26, 2020;

Fibrinolysis
Fibrinolysis and COVID-19: A plasmin paradox, Journal of Thrombosis and Haemostasis Vol. 18, Issue 9, September 2020, p2118-2122;
Study of alteplase for respiratory failure in SARS-CoV-2/COVID-19: Study design of the phase IIa STARS trial, Journal of Research and Practice in thrombosis and haemostasis Vol. 4, Issue 6, August 2020, p984-996;

Hypercoagulability
In vitro hypercoagulability and ongoing in vivo activation of coagulation and fibrinolysis in COVID-19 patients on anticoagulation, Journal of Thrombosis and Haemostasis Vol. 18, Issue 10, October 2020, p2646-2653;
COVID-19 versus HIT (heparin-induced thrombocytopenia) hypercoagulability, Thrombosis Research  2020 Dec; 196: 38-51;
Hypercoagulability of COVID-19 patients in Intensive Care Unit: A report of thromboelastography findings and other parameters of hemostasis, Journal of Thrombosis and Haemostasis Vol. 18, Issue 7, July 2020, p1738-1742;
Immunothrombosis in the Pathogenesis of COVID-19 Coagulopathy (CD177 and NET upregulation in severe COVID-19), NEJM Journal Watch, August 17, 2020;

Immunothrombosis

Immunothrombotic Dysregulation in COVID-19 Pneumonia is Associated With Respiratory Failure and Coagulopathy (granulocytes, neutrophils and platelets), Circulation Vol. 142, Issue 12, September 22, 2020;

Interleukin-1 (IL-1) and Thromboxane induction
IL-I induces Thromboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL1-receptor antagonist (IL-1Ra), Journal of Biological Regulators and Homeostatic Agents 2020 Aug 3;34(5);
Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19, Journal of Biological Regulators and Homeostatic Agents 2020 Sep 18;34(5);

Long-term cardiovascular damage by COVID-19

Outcomes of Cardiovascular MRI'ing in Patients Recently Recovered from COVID-19, JAMA Cardiology, July 27, 2020;
Long-term Health Consequences of COVID-19, JAMA, October 5, 2020;

Microthrombosis in COVID-19
The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications, Circulation Research 2020 Jul 31; 127(4): 571-587;

Platelet responses
COVID-19 patients exhibit reduced procoagulant platelet responses, Journal of Thrombosis and Haemostasis, 18 September 2020;

RAAS (Renin-Angiotensin-Aldosterone System) and cardiovascular circulatory disease
β-Arrestin-Biased Angiotensin II (Ang II) Receptor Agonists for COVID-19, Circulation Vol. 142, Issue 4, July 28, 2020;

Sepsis

The Role of Microvascular Thrombosis in Sepsis, Anaesthesia and Intensive Care Vol. 32, Issue 5, October 1, 2004;

Stroke
SARS-CoV-2 infection and its association with thrombosis and ischemic stroke: A review, The American Journal of Emergency Medicine, 30 September 2020;

Thrombocytopenia
Exploring possible mechanisms for COVID-19 induced thrombocytopenia: Unanswered questions, Journal of Thrombosis and Haemostasis Vol. 18, Issue 6, June 2020, p1514-1516;

Treatment options and management

Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory, Thrombosis Journal 2020; 18: 17;
Plasminogen improves lung lesions and hypoxemia in patients with COVID-19, QJM: An International Journal of Medicine Vol. 113, Issue 8, August 2020, p539-545;
Tissue plasminogen activator (tPA) treatment for COVID-19 associated ARDS: A case series, Journal of Thrombosis and Haemostasis Vol. 18, Issue 7, July 2020, p1752-1755;
The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection in Vitro in a Cell-Type-Dependent Manner, MDPI Viruses 2020 Jun; 12(6):629;
Anticoagulation with argatroban in patients with acute antithrombin deficiency in severe COVID-19, British Journal of Haematology Vol. 190, Issue 5, September 2020, p286-288;
IL-1 induces thromboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra), Journal of Biological Regulators and Homeostatic Agents 2020 Aug 3;34(5);
Rescue venoarterial extracorporeal membrane oxygenation (ECMO) after cardiac arrest in COVID-19 myopericarditis, Cardiovascular Revascularization Medicine, 30 September 2020;
Apirin Use is Associated with Decreased Mechanical Ventilation, ICU Admission, and In-Hospital Mortality in Hospitalized Patients with COVID-19, Anesthesia & Analgesia: October 21, 2020;
Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19?, Drugs 80, 1383-1396(2020);

Urokinase pathways towards thrombotic activity
Hypoxia Stimulates Urokinase Receptor Expression Through a Heme Protein-Dependent Pathway, ASH Blood Journal Vol. 91, Issue 9, May 1, 1998;

V and X Factors and therapeutic inhibition options

(Xa Factor) Response to "Studies on hemostasis in COVID-19 careful reporting of the laboratory methods, their significance and their limitation": don't throw the baby out with the bathwater (on testing with anti-Xa kit), Journal of Thrombosis and Haemostasis, 28 August 2020;
Dual inhibition of Factor XIIa and Factor XIa as a therapeutic approach for safe thromboprotection, Journal of Thrombosis and Haemostasis, 12 October 2020;
COVID-19 and Blood Clots (Factor V activity strongest among all clinical parameters), Harvard News & Research September 09, 2020;

maandag 19 oktober 2020

Extensive reading recommendations on SARS-CoV-2/COVID-19: all mechanisms involved (Part 6)


Factors involved in SARS-CoV-2/COVID-19

Activated endothelium as a source of Acute Lung Injury (ALI)/ARDS
Angiopoietin-2, permeability oedema, occurrence and severity of ALI/ARDS in septic and non-septic critically ill patients, BMJ Thorax Journal Vol 63, Issue 10, October 2008;
Endothelial biomarkers in human sepsis: pathogenesis and prognosis for ARDS
, Pulmonary Circulation 2018 Apr-Jun; 8(2);

Acute Lung Injury (ALI)
A Perspective on Erythropoietin as a Potential Adjuvant Therapy for Acute Lung Injury (ALI)/ARDS in Patients with COVID-19, Archives of Medical Research 2020, Aug 11;

Coagulation
Thromboinflammation and the hypercoagulability of COVID-19, Journal of Thrombosis and Haemostasis, 13 April 2020;

Embolism
Pulmonary embolism in COVID-19 patients: a French multicentre cohort study, European Heart Journal Vol. 41, Issue 32, 21 August 2020, p3058-3068;

Hypoxia and HIF as a link between sepsis and thrombosis
Hypoxia and HIF activation as a possible link between sepsis and thrombosis, Thrombosis Journal 2019; 17: 16;
The stimulation of thrombosis by hypoxia, Thrombosis Research Vol. 181, p77-83, September 01, 2019;
Hypoxia response and acute lung and kidney injury: possible implications for therapy of COVID-19, Clinical Kidney Journal 2020 Aug; 13(4): 494-499;
Innate immunity during SARS-CoV-2: evasion strategies and activation trigger hypoxia and vascular damage, Clinical and Experimental Immunology, Journal of Translational Immunology, 26 September 2020;
COVID-19: hemoglobin, iron and hypoxia beyond inflammation: A narrative review, Clinics and Practice 2020 May 19; 10(2): 1271;
miRNAs regulate the HIF switch during hypoxia: a novel therapeutic target, Angiogenesis 2018; 21(2): 183-202;

Hypoxia and Reactive Oxygen Species (ROS) (oxidative stress)
Keeping the engine primed: HIF factors as key regulators of cardiac metabolism and angiogenesis during ischemia, Journal of Molecular Medicine 2007 Dec;85(12):1309-15;
Role of oxidative stress and NFkB in hypoxia-induced pulmonary edema (curcumin as a NFkB blocker attenuates hypoxia-induced edema), Experimental Biology and Medicine Vol. 233, Issue 9, 2008;

Pathogenesis and structure of SARS-CoV-2
Does the pathogenesis of SARS-CoV-2 decrease at high-altitude?, Respiratory Physiology & Neurobiology Vol. 277, June 2020;
Mechanisms of Coronavirus Cell Entry Mediated by the Viral Spike Protein, MDPI Viruses 2012 Jun;4(6): 1011-1033;
Structure, Function and Evolution of Coronavirus Spike Proteins, Annual Reviews Virology 2016 Sep 29; 3(1): 237-261;
Cleavage of the SARS Coronavirus Spike Glycoprotein by Airway Proteases Enhances Virus Entry into Human Bronchial Epithelial Cells in Vitro, PLoS 2009; 4(11): e7870;

Pattern Recognition Receptors, Interferon pathways and cytokine cascades
Innate immunity during SARS-CoV-2: evasion strategies and activation trigger hypoxia and vascular damage, Clinical and Experimental Immunology, Journal of Translational Immunology, 26 September 2020;

Pulmonary vascular (right ventricular) consequences of COVID-19

Novel insights on the pulmonary vascular consequences of COVID-19, Lung Cellular and Molecular Physiology 2020 Aug 1; 319(2): L277-288;

Sepsis
Sepsis and septic shock: endothelial molecular pathogenesis associated with vascular thrombotic disease, Thrombosis Journal 2019; 17: 10;
Endothelial biomarkers in human sepsis: pathogenesis and prognosis for ARDS, Pulmonary Circulation 2018 Apr-Jun; 8(2);

Therapeutics and possible treatment options for COVID-19

Oxytocin as a Potential Adjuvant against COVID-19 Infection, Endocrine, Metabolic & Immune Disorders Drug Targets 2020, Sep 10;
Prophylactic efficacy of Quercetin in ameliorating the hypoxia induced vascular leakage in lungs of rats, PLoS One 2019; 14(6);
Nifedipine inhibits hypoxia induced transvascular leakage through downregulation of NFkB, Respiratory Physiology & Neurobiology Vol. 183, Issue 1, 31 July 2012, p26-34;

zaterdag 17 oktober 2020

Extensive reading recommendations on SARS-CoV-2/ COVID-19: all mechanisms involved (Part 5)

So many factors involved! A non-exhaustive overview of factors involved in COVID-19

ADAMTS-13

All complications of COVID-19

Overview of lethal human coronaviruses, Signal Transduction and Targeted Therapy 2020; 5: 89;

B cell profiles
Illuminating vitamin D effects on B cells- the Multiple Sclerosis perspective, Immunology 2016 Mar; 147(3): 275-284;

Cardiovascular complications of COVID-19
Anticipating the long-term cardiovascular effects of COVID-19, Journal of Thrombosis and Thrombolysis 2020 Sep 3: 1-13;
COVID-19 and Heart Failure With Preserved Ejaction Fraction, JAMA September 30, 2020;

Coagulation
Unique transcriptional changes in coagulation cascade genes in SARS-CoV-2 infected lung epithelial cells: A potential factor in COVID-19 coagulopathies, NIH MedRvix Preprint, 2020 Jul 7;
COVID-19 and Coagulopathy:  FAQ, ASH 24 September 2020;

Development of therapeutics for COVID-19

Challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeutics, Journal of Antimicrobial Chemotherapy Vol. 75, Issue 9, September 2020, p2381-2383;
COVID-19/SARS-CoV-2 Infection: Lysosomes and Lysosomotropism Implicate New Treatment Strategies and Personal Risks, International Journal of Molecular Sciences 2020 Jul; 21(14): 4953;
SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic, Annals of Clinical Microbiology and Antimicrobials 2020; 19: 40;
Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing, Nature 586, 113-119(2020);

Embolism
COVID-19 and Pulmonary Embolism: FAQ, 22 September 2020;

Immunology
T-helper type I cytokine release is enhanced by in vitro zinc supplementation due to increased natural killer cells, Nutrition Vol. 23, Issue 2, February 2007, p157-163;
Zinc signals and immune function (NK-, T- and B-cells), BioFactors Vol. 40, Issue 1, January/February 2014, p27-40;

Inflammatory response to SARS-CoV-2 in COVID-19

Understanding COVID-19: From Origin to Potential Therapeutics, International Journal of Environmental Research and Public Health 2020 Aug;17(16): 5904;

Inhibitors to explore
Coronaviruses and Nature's Pharmacy for the Relief of COVID-19 (inhibitory properties of natural compounds), Revista Brasileira de Farmacognosia 2020 Oct 6: 1-19;

Interferon
Attenuated Interferon and Proinflammatory Response in SARS-CoV-2-Infected Human Dendritic Cells is Associated with Viral Antagonism of STAT1 Phosphorylation, The Journal of Infectious Diseases Vol. 222, Issue 5, 1 September 2020;
Auto-antibodies against type I IFNs in patients with life-threatening COVID-19, AAAS Science, 24 Sep 2020 (treatment with injected or nebulized IFN-β may have beneficial effects);

Macrophages
Attenuated Interferon and Proinflammatory Response in SARS-CoV-2-Infected Human Dendritic Cells is Associated with Viral Antagonism of STAT1 Phosphorylation, The Journal of Infectious Diseases Vol. 222, Issue 5, 1 September 2020;

Nsp3 and STAT1 in cytokine storm syndrome
A Putative Role of de-Mono-ADP-Ribosylation of STAT1 by the SARS-CoV-2 Nsp3 Protein in the Cytokine Storm Syndrome of COVID-19, Viruses 2020 Jun; 12(6): 646;

Oxidative Stress
Zinc status is associated with inflammation, oxidative stress, lipid and glucose metabolism, The Journal of Physiological Sciences 2018; 68(1): 19-31;
Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease, Verhandelingen van de Koninklijke Academie voor Geneeskunde van België 2008;70(3):193-219;

Pathogenesis, evolution and structure of SARS-CoV-2
Rampant C > U Hypermutation in the Genomes of SARS-CoV-2 and Other Coronaviruses: Causes and Consequences for their Short- and Long-Term Evolutionary Trajectories, mSphere 2020 May-Jun; 5(3);
Mutation Patterns of Human SARS-CoV-2 and Bat RATG13 Coronavirus Genomes are Strongly Biased Towards C > U Transitions, Indicating Rapid Evolution in Their Hosts, Genes (Basel.) 2020 Jul; 11(7):761;
Molecular epidemiology, evolution and phylogeny of SARS coronavirus, Infection, Genetics and Evolution 2019 Jul; 71: 21-30;
Overview of lethal human coronaviruses, Signal Transduction and Targeted Therapy 2020; 5: 89;
2017 Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus, PLoS Pathogens 2017 Nov;13(11);
Signal hotspot mutations in SARS-CoV-2 evolve as the virus spreads and actively replicates in different parts of the world, Virus Research 2020 Nov; 289: 198170;

Possible treatment options
Early Nutritional Interventions with Zinc, Selenium and Vitamin D for Raising Anti-Viral Resistance Against Progressive COVID-19, MDPI Nutrients 2020, 12(8), 2358;
Current State of Evidence: Influence of Nutritional and Nutrigenetic Factors on Immunity in the COVID-19 Pandemic Framework, MDPI Nutrients 2020, 12(9), 2738;
A Hypothesis for the Possible Role of Zinc in the Immunological Pathways Related to COVID-19 Infection, Frontiers in Immunology 2020; 11:1736;
Statin therapy and SARS-CoV-2: an available and potential therapy?, European Heart Journal of Cardiovascular Pharmacotherapy 2020, May 7 2020;
Nutraceuticals have potential for boosting the Type I Interferon (IFN) response to RNA viruses, including influenza and coronavirus, Progress in Cardiovascular Diseases 2020 May-June; 63(3): 383-385;
Azithromycin and Glucosamine May Amplify the Type I Interferon (IFN) Response to RNA viruses in a complementary fashion, Immunology Letters 2020 Sep 28;

Sepsis and septic shock
Sepsis and septic shock: endothelial molecular pathogenesis associated with vascular microthrombotic disease, Thrombosis Journal 2019; 17: 10;

dinsdag 13 oktober 2020

Extensive reading recommendations on SARS-CoV-2/ COVID-19: all mechanisms involved (Part 4)

Factors involved in SARS-CoV-2/ COVID-19

Autophages
Autophagy markers as mediators of lung injury-implication for therapeutic intervention, Life Science 2020 Nov 1; 260: 118308;
Autophagy augmentation to alleviate immune response dysfunction and resolve respiratory and COVID-19 exacerbations, MDPI Cells 2020, 9(9), 1952;

Cardiovascular disease caused by SARS-CoV-2
Potential Effects of Coronaviruses on the Cardiovascular System: A Review, JAMA Cardiology 2020;5(7):831-840;
Cardiac dysfunction and thrombocytopenia-associated multiple organ failure inflammation phenotype in a severe paediatric case of COVID-19, Lancet Child & Adolescent Health Vol. 4, Issue 7, p552-554, July 01, 2020;
ACE2 down-regulation may contribute to the increased thrombotic risk in COVID-19, European Heart Journal Vol. 41, Issue 33, 1 September 2020;

Coagulation
The unique characteristics of COVID-19 coagulopathy, Critical Care 2020; 24: 360;
Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A new Challenge, Thrombosis and Haemostasis Vol. 120, Issue 6, June 2020, p949-956;
Coagulation abnormalities and thrombosis in patients with COVID-19, Lancet Haematology 2020 Jun; 7(6): e438-440;
COVID-19 coagulopathy vs Disseminated Intravascular Coagulation (DIC), Blood Advances 2020, Jun 23; 4(12): 2850;
Viral Coagulopathy in Patients With COVID-19: Treatment and Care, Clinical and Applied Thrombosis/Hemostasis 2020 Jan-Dec; 26;
Procoagulatio, hypercoagulatio és fibrinolysis "shut down" detected with ClotPro viscoelastic tests in COVID-19 patients, Orvosi Hetilap Vol. 161, Issue 22, 01 May 2020;
Thromboelastic Results and Hypercoagulability Syndrome in Patients With COVID-19 Who Are Critically Ill, JAMA Infectious Diseases 2020; 3(6);

Comparative pathogenesis
Comparative pathogenesis of COVID-19, MERS, and SARS (2003) in a nonhuman primate model, AAAS 2020 May 29; 368(6494): 1012-1015;
Emergence and molecular mechanisms of SARS-CoV-2 and HIV to target host cells and potential therapeutics, Infection, Genetics and Evolution 2020 Oct. 6: 104583;

Cytokine cascade
Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines, Open Biology 2020 Sep; 10(9): 200160;

Fibroblasts
Fibroblasts and Their Pathological Functions in the Fibrosis of Aortic Valve Sclerosis and Atherosclerosis, Journal of Biomolecules 2019 Sep; 9(9): 427;

Hematology
Coronavirus Disease 2019 (COVID-19): A Haemotologist's Perspective, Acta Haematologica 2020, Jul 28: 1-14;

Hemostasis in COVID-19
Hemostasis profile in COVID-19, SciELO July 3, 2020;

Hyperinflammatory Syndrome (cHIS)
Clinical criteria for COVID-19 -associated hyperinflammatory syndrome (cHIS): a cohort study, Lancet Rheumatology, September 29, 2020;

Immunity and immunomodulation
Targeting the NLRP3 Inflammasome in Severe COVID-19, Frontiers in Immunology 2020; 11:1518;
Breadth of concomitant immune responses prior to patient recovery: a case report from non-severe COVID-19 (ASCs, Tfh, CD4+ and CD8+), Nature Medicine 2020 March 16: 1-3;

Interferons (IFN-x)

Evasion of type I Interferon by SARS-CoV-2, Cell Reports 2020 Oct 06; 33(1): 108234;

Interleukins (IL- )

Interleukin-1beta- A Friend or Foe in Malignancies?
, International Journal of Molecular Science 2018 Aug; 19(8): 2155;
Transient expression of IL-1beta induces Acute Lung Injury and chronic repair leading to pulmonary fibrosis, Journal of Clinical Investigation 2001 Jun 15; 107(12): 1529-1536;
IL-6 trans-signaling induces PAI-1 from vascular endothelial cells in cytokine release syndrome, PNAS 2020 Sep 8; 117(36): 22351-22356;
Anti-Cytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Artherothrombosis, Journal of Circulation Research 2019 Feb; 124 (3): 537-450;

NLRP3 Inflammasome
SARS-CoV-2 infection and overactivation of NLRP3 inflammasome as a trigger of  "cytokine storm" and risk factor for damage of hematopoietic cells, Leukemia 2020; 34(7): 1726-1729;
NLRP3 Inflammasome- A Key Player in Antiviral Responses, Frontiers in Immunology 2020; 11: 211;
Severe COVID-19: NLRP3 Inflammasome dysregulated, Frontiers in Immunology 2020; 11: 1580;

Nsp13, nsp14, nsp15
SARS-Coronavirus-2 Nsp13 Possesses NTPase and RNA Helicase Activities That Can Be Inhibited by Bismuth Salts, Virologica Sinica 2020 Jun; 35(3): 321-329;
SARS-CoV-2 nsp13, nsp14, nsp15 and ORF6 function as potent interferon antagonists, Emerging Microbes & Infections 2020; 9(1): 1418-1428;

Oxidative Stress (ROS) and shortage of antioxidants
Oxidative Stress as Key Player in SARS-CoV Infection, Archives of Medical Research 2020 Jul; 51(5): 384-387;

ORF-x protein of SARS-Coronavirus-2
SARS-CoV-2 nsp13, nsp14, nsp15 and ORF6 function as potent interferon antagonists, Emerging Microbes & Infections 2020; 9(1): 1418-1428;
SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is further increased by a naturally occurring elongation variant, Immunology Network (preprint available from BioRxiv), May 12, 2020;

Pathogenesis and structure of SARS-CoV-2
Pathophysiology of COVID-19: Mechanisms Underlying Disease Severity and Progression, Journal of Physiology Vol. 35, Issue 5, September 2020, p288-301;
Beyond shielding: the roles of glycans in the SARS-CoV-2 Spike Protein, ACS Cent. Sci. 2020, September 23, 2020;
Differential expression of ACE2 in the respiratory tracts and its relationship to COVID-19 pathogenesis, EBioMedicine Vol. 60, Issue 103004, October 01, 2020;

Platelets

Platelet functions and activities as potential hematologic parameters related to Coronavirus Disease 2019 (COVID-19), Platelets Journal Vol. 31, Issue 5, 2020;
Platelet Activation is Associated With Myocardial Infarction in Patients With Pneumonia, Journal of the American College of Cardiology Vol. 64, Issue 18, 4 November 2014, P1917-1925;

RNA Sequence and establishing the gold standard in RT-PCR
The establishment of reference sequence for SARS-CoV-2 and variation analysis, Journal of Medical Virology Vol. 92, Issue 6, June 2020, p667-674;
False-positive COVID-19 results: hidden problems and costs (false-positives estimated between 0,8 and 4%), Lancet Respiratory Medicine, September29,  2020;

Sepsis
SARS-CoV-2 and viral sepsis: observations and hypotheses, Lancet Hypothesis Vol. 395, Issue 10235, P1517-1520, May 09, 2020;

T-cell profile

Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19 (cytokine storms marked by more nonfunctional CD4+ T cells and higher senescent CD8+ T cells), Clinical Immunology 2020 Jul; 216: 108464;

Thrombotic Thrombocytopenic Purpura (TTP)

Immune thrombocytopenic purpura after COVID-19 infection, International Journal of Laboratory Hematology 2020, Sep 20: 10.1111;

Treatment options
Is Antioxidant Therapy a Useful Complementary Measure for COVID-19 Treatment? An Algorithm for its Application, Medicina Kaunas 2020 Aug; 56(8): 386;
Kaempferol Alleviates the Interleukin-1beta-Induced Inflammation in Rat Osteoarthritis Chondrocytes via Suppression of NF-kB, Medical Science Monitor 2017; 23: 3925-3931;
Possible effect op epinephrine in minimizing COVID-19 severity: a review, Journal of International Medical Research 2020 Sep; 48(9);
Early outcomes with utilization of tPA (tissue plasminogen activator) in COVID-19-associated respiratory distress (ARDS): A series of five cases, Journal of Trauma and Acute Care Surgery: September 2020, Vol. 89, Issue 3, p448-452;
CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement, Stem Cell Reviews and Reports 2020 Apr 20: 1-7;
Role of melatonin in the treatment of COVID-19; as an adjuvant through cluster differentiation CD147, Molecular Biology Reports 2020 Sep 12: 1-5;
ADAMTS13: An Emerging Target in Stroke Therapy, Frontiers in Neurology, 17 July 2019;
The Potential Impact of Zinc Supplementation on COVID-19, Frontiers Nutritional Immunology, 10 July 2020;
B cell activation and proliferation increase intracellular zinc levels, Journal of Nutritional Biochemistry 2019 Feb; 64: 72-79;

Urokinase
Early outcomes with utilization of tPA (tissue plasminogen activator) in COVID-19-associated respiratory distress (ARDS): A series of five cases, Journal of Trauma and Acute Care Surgery: September 2020, Vol. 89, Issue 3, p448-452;